Acadia Pharmaceuticals Inc. Data Breach Notice (Oregon Attorney General)

The filing from Acadia Pharmaceuticals Inc. means that personal information belonging to 14,065 people is now outside the company’s control. If you received a notification letter, some of your records were included in that group.

What the Exposure Actually Changes for You

The Oregon Attorney General’s office received notice of the incident on December 04, 2024. The record lists only one category: personal information. No passwords, no financial account numbers, no Social Security numbers, and no government identifiers were named in the filing. That is genuinely good news. The most dangerous pieces of data that usually enable immediate identity theft or new-account fraud are not reported as exposed here.

Yet the information that was involved still carries permanent risk. Once personal details leave a company, they cannot be taken back. They can be combined with data from other breaches to build fuller profiles that support fraud, phishing, or impersonation attempts months or years from now.

Why Personal Information Remains Valuable to Thieves

Names paired with addresses, dates of birth, or contact details are frequently used as building blocks. Criminals buy or trade these fragments across dark-web markets and wait until they collect enough matching records to attempt tax-refund fraud, medical identity theft, or convincing spear-phishing emails. Because Acadia Pharmaceuticals is a biopharmaceutical company, the people affected are likely patients, clinical-trial participants, or customers who interacted with the company about its medications. Their records therefore tie directly to health conditions or treatments, which adds another layer of sensitivity even though specific medical data fields were not listed.

The filing does not state when the incident occurred, so there is no way to calculate how long the information may have been accessible. The only reliable way to know whether your own records were part of the 14,065 is the letter itself. If you have not received one, it is likely you were not affected. However, if you have moved since the time you last provided information to Acadia Pharmaceuticals, the letter may have gone to an old address. In that case you should contact the company directly to confirm your status.

The Limits of What This Filing Tells Us

This notification establishes only that a breach happened, that personal information was involved, and that 14,065 Oregon residents were reported as affected. It does not disclose the root cause, whether data was copied or simply viewed, or the precise fields beyond the broad term “personal information.” Those uncertainties matter. Without them, it is impossible to judge how targeted or sophisticated the event was. What remains certain is that the exposed personal information cannot be reissued or cancelled the way a credit card can.

How Long the Risk Lasts

Unlike a compromised password or credit-card number, personal details do not expire. A name and address tied to a past relationship with Acadia Pharmaceuticals can reappear in future data sets for decades. That longevity is why monitoring and vigilance replace one-time fixes. The absence of passwords in the exposed data means you do not need to change any Acadia-related credentials, but you should treat any future unsolicited contact claiming to be from the company with extra caution.

Practical Steps That Address This Specific Exposure

• Place a fraud alert with the three major credit bureaus. Even without Social Security numbers listed, a fraud alert forces lenders to verify your identity before opening new accounts in your name.
• Review your Explanation of Benefits statements from any health plans. Watch for claims you did not receive treatment for, which could signal medical identity theft built from the personal details now circulating.
• Monitor your tax accounts closely this filing season. Identity thieves sometimes use personal information to file fraudulent returns; early detection lets you respond before refunds are diverted.
• Treat unexpected calls, texts, or emails referencing Acadia Pharmaceuticals as suspicious. The combination of personal details and health context makes targeted phishing more convincing.
• Keep records of the notification letter and any correspondence with the company. Should problems appear later, these documents establish when you were informed and what the company acknowledged.

The record is narrow by design. It gives the number of people affected, the filing date, and the broad data category. Everything else — motive, method, exact impact — remains unknown. What matters most to you is that your personal information, once exposed, stays exposed. The letter is the only practical test of whether you are in the group of 14,065. If you have it, the steps above reduce what an attacker can do with the information. If you have not received one, the filing suggests you were not included, but anyone uncertain because of a recent move should reach out to Acadia Pharmaceuticals to verify.